Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
Ana Luiza Drumond‐Bock, Magdalena Bieniasz
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Regulation of programmed cell death by Brd4
Jinfeng Hu, Dun Pan, Guo Li, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 12
Open Access | Times Cited: 45
Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy
Yihong He, Yan Ju, Yuzhu Hu, et al.
Journal of Controlled Release (2023) Vol. 354, pp. 155-166
Closed Access | Times Cited: 25
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor
Na Liu, Rui Ling, Xiang Tang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Targeted therapy in high grade serous ovarian Cancer: A literature review
Kaitlyn Dinkins, Wade Barton, Lauren Wheeler, et al.
Gynecologic Oncology Reports (2024) Vol. 54, pp. 101450-101450
Open Access | Times Cited: 6
MicroRNA-377: A therapeutic and diagnostic tumor marker
Iman Akhlaghipour, Negin Taghehchian, Amir Sadra Zangouei, et al.
International Journal of Biological Macromolecules (2022) Vol. 226, pp. 1226-1235
Closed Access | Times Cited: 24
Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription
Xiaoyang Yu, Quanxin Long, Sheng Shen, et al.
Antiviral Research (2023) Vol. 211, pp. 105552-105552
Open Access | Times Cited: 13
Clinicopathological and prognostic factor analyses of primary fallopian tube carcinoma and high-grade serous ovarian cancer: a single-institution retrospective study
Mengyan Tu, Xueyan Gao, Tianchen Guo, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Ectopic expression of testis-specific transcription elongation factor in driving cancer
Bin Zheng, Marta Iwanaszko, Shimaa Soliman, et al.
Science Advances (2025) Vol. 11, Iss. 11
Open Access
Development and validation of a prognostic nomogram for ovarian clear cell carcinoma: a study based on the SEER database and a Chinese cohort
Yao Shen, Fei Xi, Pingge Zhao, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
Yihong He, Xin Zan, Junming Miao, et al.
Materials Today Bio (2022) Vol. 16, pp. 100423-100423
Open Access | Times Cited: 21
PROTACS: A technology with a gold rush-like atmosphere
Yuwei Wang, Li Lan, Min Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115037-115037
Closed Access | Times Cited: 21
Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion
Yi Liu, Hejing Liu, Miaomiao Ye, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 9
Open Access | Times Cited: 11
A comprehensive review of BET-targeting PROTACs for cancer therapy
Xiaoli Zhou, Fang Zhao, Yong-Tao Xu, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 73, pp. 117033-117033
Closed Access | Times Cited: 17
Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)
Voraporn Yongprayoon, Napasporn Wattanakul, Winnada Khomate, et al.
Oncology Reports (2024) Vol. 51, Iss. 6
Open Access | Times Cited: 3
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W. Garsed, George Au‐Yeung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines
Ziqin Yan, Xilin Lyu, Dongze Lin, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115381-115381
Closed Access | Times Cited: 8
NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion
Prerana Jha, Vaishakhi Trivedi, Nandini Menon, et al.
Cancer Research Statistics and Treatment (2024) Vol. 7, Iss. 1, pp. 110-116
Open Access | Times Cited: 2
Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine
Lele Ye, Xinya Tong, Kan Pan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
PROTACs in Gynecological Cancers: Current Knowledge and Future Potential as a Treatment Strategy
Fatemeh Movahed, Zahra Ourang, Razieh Neshat, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155611-155611
Closed Access | Times Cited: 2
Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets
Yongli Situ, Quanyan Liang, Ziying Zeng, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 6
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer
Laura Pascual‐Reguant, Queralt Serra‐Camprubí, Debayan Datta, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 12
Open Access | Times Cited: 6
Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression
Sidra Shahid, Marlena Pantakani, Lutz Binder, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7453-7453
Open Access | Times Cited: 9
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
Shumei Wang, Kang Lei, Hsien‐Tsung Lai, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 4, pp. 1178-1190
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top